Sector News

Forget megadeals, Pfizer CEO-to-be Bourla says. They're just too distracting

October 31, 2018
Life sciences

In Pfizer’s farewell earnings report for outgoing CEO Ian Read, successor Albert Bourla gave a first glimpse into what he has planned for the Big Pharma—and it doesn’t include big M&A deals.

With what Bourla called “the best pipeline in our history,” the company needs to deploy its capital to the right places, keep its pipeline flowing and execute on its drug launches, the incoming CEO said, as it enters “an era of sustained growth.”

“In this context, I would reiterate that we continue not to see the need for any large-scale M&A activity at this time,” Bourla said on the company’s third-quarter earnings call.

Just like that, Bourla put to rest whatever megadeal speculation might remain among pharma watchers, who’ve come to expect a major Pfizer buyout—or buyout attempt, in the case of AstraZeneca and Allergan—at regular intervals.

Make no mistake, this decision isn’t about Pfizer’s ability to come up with the money for a megabuyout. In fact, Bourla pointed out it has plenty of balance sheet power to buy whatever it might want. Instead, it’s about how destructive such deals can be.

“We’re going to enter into a period of growth post-2020, and we need to make sure we execute right now on our pipeline [and] on our commercial launches and market preparations,” said Bourla on the Tuesday call. “And large M&A typically comes with a big integration that’s destructive to operations.”

But he added that the company will still scan for smaller deals that could enhance its growth trajectory or its pipeline.

Pfizer has suffered unprecedented losses of exclusivity in recent years. But Bourla said he expects that will be capped by pain drug Lyrica, which turned in $3.46 billion in U.S. sales last year but will lose patent protections in the U.S. in December.

Give it another two years, he said, and the impact from generics will stabilize—and it’ll be showtime for several of the potential breakthrough sellers already on the market or in the company’s deep pipeline, which together comprise 15 potential blockbusters in five years, he said.

Before those pipeline products kick in, the company’s growth is coming from breast cancer drug Ibrance and rheumatoid arthritis treatment Xeljanz—the two marketed assets that Bourla said excites him the most, though both fell short of analyst expectations in the third quarter.

For the third quarter, Ibrance ginned up $1.03 billion in sales, up 17%, even though the U.S. posted a $5 million decline. Outside the U.S., sales almost doubled, driven by continued uptake in Europe and a recent launch in Japan. And the next phase of growth has yet to come for Ibrance, according to Pfizer Innovative Health chief John Young. It is in the adjuvant—or early breast cancer—setting, which encompasses a population roughly double the size of the current metastatic population, Young said on the call.

Xeljanz third-quarter sales were up 24% to $432 million. Another bright spot was Inflectra, the company’s biosimilar to Remicade. The drug climbed 48% to $166 million in the three months.

Revenue from China also rocketed by double digits. The country breathed some new life into the company’s legacy established products (such as Lipitor), which, along with some generics, are part of the newly rejigged Established Medicines business. Bourla said he sees great potential in China and plans to relocate some top managers there because it’s delivering most of the growth in the established business.

Heading into 2019, the company will have a new CEO, a new company structure and management team, as announced recently by Pfizer. And Bourla said it is already taking steps to simplify the organization, increase expense control and reduce organizational layers to generate savings and expedite decision making.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach